No Image Available

Cefepime (4th Gen) Injectable (IV/IM)

Form: Injectable (IV/IM)

Strength: 1 g, 2 g, 4 g per vial

Reference Brands: Maxipime(US & EU)

Category: Antibiotics

Cefepime IV injection is approved in the EU and US for treating severe bacterial infections, including pneumonia, sepsis, and febrile neutropenia. In the EU, brands like Maxipime are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, quality assurance, and pharmacovigilance plans, for approval and continuous safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for cefepime injection, ensuring adherence to European and US standards for safe, effective treatment of serious infections.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Colistin (Polymyxin E) Inhalation Solution (Nebulizer)

Strength: 75 mg/2 mL

Form: Inhalation Solution (Nebulizer)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Colistin (Polymyxin E)

Strength: 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial

Form: Injectable (IV/IM/SC)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Fosfomycin Oral Sachets or Powder for Suspension

Strength: 3g in a sachet

Form: Oral Sachets or Powder for Suspension

Reference Brands: Zyflo(US)

View Details Get Enquiry
Fosfomycin IV

Strength: 2 g, 4g per vial

Form: Intravenous (IV)

Reference Brands: Zyflo(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.